Compumedics Limited (ASX:CMP) Targets Recurring Revenue With Somfit and Nexus 360

Aditi Sarkar

11 November 2026 04:33 PM AEDT

Compumedics Limited (ASX:CMP) Targets Recurring Revenue With Somfit and Nexus 360

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

• Compumedics expected FY26 shipped and invoiced Revenue of approximately AUD 60.3 million in its July update.

• The indicated result represented around 18% growth on FY25 and remained subject to audit at announcement.

• Somfit and Nexus 360 software-as-a-service Recurring Revenue grew approximately 70%, according to the company update.

• The company lodged a November investor update and recently announced changes in its finance Leadership and company secretary roles.

Sleep technology and recurring software revenue are central to the recent operating story for Compumedics Limited (ASX:CMP). The medical diagnostics developer reported record expected FY26 shipped and invoiced revenue in its July update, while continuing its work on connected monitoring platforms.

Market Setting

Compumedics shares were up about 4.2% to around 25 cents on Wednesday 11 November 2026, around 2:40pm AEDT . Volume was only about 21,000 shares, so the move reflects very thin trading and a small number of trades can shift the price.

Diagnostic Technology

Compumedics, based in Abbotsford, Victoria, and listed since December 2000, develops, manufactures and sells diagnostic technology for sleep, brain and ultrasonic blood-flow monitoring. Its products include sleep diagnostic systems, EEG and neurology equipment, magnetoencephalography (MEG) systems, and the Somfit connected sleep device and Nexus 360 software platform.

Recent Operating Results

In a Business update dated 6 July 2026, the company said it expected record FY26 shipped and invoiced revenue of about AUD 60.3 million, up roughly 18% on FY25 and subject to audit. It reported sales orders of about AUD 62.7 million and said Somfit and Nexus 360 software-as-a-service recurring revenue grew about 70%.

That revenue was modestly below the April 2026 revised guidance of AUD 62 million to AUD 65 million. The company attributed the gap mainly to timing, including MEG shipment delays linked to higher helium prices, which it said had since been resolved, and a cautious approach to the commercial release of Somfit D in the United States. It said FY26 EBITDA was expected to grow and that it was targeting further double-digit revenue growth in FY27, with EBITDA growing faster than revenue. The company also announced the resignation of non-executive director Christopher Barys in that update.

Key Operating Considerations

Compumedics is a small company, with a Market Value of roughly AUD 48 million to AUD 50 million. Its shares have traded between 21.5 cents and 45 cents over the past 52 weeks, and them down about 25% in 2026 so far. The company has already fallen short of its own revenue guidance once this year, MEG sales depend on timely manufacture and shipment, and the US release of Somfit D has not yet been confirmed. Thinly traded stocks of this size can also move sharply on small volumes.

Next Business Milestones

The company has said it is working towards the US release of Somfit D and towards converting its order book into shipped revenue through FY27. a forecast interim result date of about 24 February 2027, which is a forecast rather than a company-confirmed date.

FAQs

Q: What products are central to the recurring revenue strategy?

A: Somfit devices and the Nexus 360 software platform.

Q: What FY26 revenue did Compumedics expect in July?

A: About AUD 60.3 million, subject to audit.

Q: How much did SaaS recurring revenue grow?

A: Approximately 70%.

Q: Was the November investor update detailed in the draft?

A: No. Its underlying contents were unavailable.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.